Emerging Biomarkers for the Selection of Advanced NSCLC-Affected Immunotherapy Patients
Immunotherapy in the form of ICIs has revolutionized advanced NSCLC treatment algorithms, with ICI-containing combination treatments being the latest addition to approved regimens. However, PD-L1 still represents the only routinely assessed and validated biomarker apart from genetic drivers testing,...
Збережено в:
| Автори: | , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
MDPI AG
2021-06-01
|
| Серія: | Journal of Molecular Pathology |
| Предмети: | |
| Онлайн доступ: | https://www.mdpi.com/2673-5261/2/2/17 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|